Background {#Sec1}
==========

Nitrogen containing heterocyclic ring such as pyrimidine is a promising structural moiety for drug design. Pyrimidine derivatives form a component in various useful drugs and are associated with many biological and therapeutic activities. Condensed pyrimidines have been reported as antimicrobial \[[@CR1]\]--\[[@CR3]\], anti-inflammatory \[[@CR4]\],\[[@CR5]\], analgesic \[[@CR6]\],\[[@CR7]\], anticancer \[[@CR8]\]--\[[@CR10]\], anti-HIV \[[@CR11]\], antitubercular, antimalarial, diuretic, and cardiovascular disease \[[@CR12]\] (Scheme [1](#Sch1){ref-type="fig"}).Scheme 1**Chemical structure of BT** ~**10**~ **M.**

The present work is a synthesis, a biological evaluation and validation of novel pyrimidine derivatives. Research workers have synthesized 50 pyrimidine derivatives (T~1~M-T~10~M, T~1~P-T~10~P, BT~1~M-BT~10~M, BT~1~P-BT~10~P, CT~1~M-CT~5~M, and CT~1~P-CT~5~P). Among them, BT~10~M exhibited maximum antimicrobial, anti-inflammatory, and analgesic activity. Hence, a validation study was done on BT~10~M. BT~10~M is chemically \[6-Bromo-3-(6-(2,6-dichlorophenyl)-2-(morpolinomethylamino) pyrimidine4-yl) -2H-chromen-2-one\]. It is a yellow crystalline powder with a molecular formula of C~24~H~19~BrCl~2~N~4~O~3~ and a molecular weight of 562.24. It is a potent antimicrobial, analgesic and anti-inflammatory agent among all the synthesized derivatives. Hence, the aim of present investigation is to develop a simpler, rapid, and cost-effective analytical method for the determination of pyrimidine derivative (BT~10~M) in bulk dosage form suitable for routine quality control analysis.

Method validation is the process used to confirm that analytical procedure employed for a specific test is suitable for its intended use. It is an integral part of any good analytical practice. Methods need to be validated or revalidated \[[@CR13]\].

Methods {#Sec2}
=======

Chemical and reagent {#Sec3}
--------------------

BT~10~M was synthesized by research workers and then validated. Methanol and acetonitrile (1:1) were used throughout spectrophotometric method development and validation.

Instrumentation {#Sec4}
---------------

The method was performed on a double-beam ultraviolet-visible (UV-VIS) spectrophotometer (Shimadzu model 1700 (Shimadzu, Kyoto, Japan)) having two matched quartz cells with a 1-cm light path.

Determination of maximum wavelength (*λ*~max~), methodology, and sample preparation {#Sec5}
-----------------------------------------------------------------------------------

About 50 mg of BT~10~M was weighed accurately and transferred into a 50-ml volumetric flask and dissolved in 25 ml of methanol and acetonitrile (1:1) and made up to the volume with the same solvent mixture to give a standard concentration of 1,000 μg/ml. Transfer 5 ml of above solution into the 50-ml volumetric flask, dilute, and made up to the volume with the same solvent mixture to get a standard concentration of 100 μg/ml. This solution was scanned against a blank over the entire UV-VIS wavelength of 200 to 400. Based on the spectrum, a *λ*~max~ of 275 nm was selected for further analysis.

Results {#Sec6}
=======

The method was validated with respect to linearity, accuracy, precision, specificity, robustness, ruggedness, LOD, and LOQ in Table [1](#Tab1){ref-type="table"}.Table 1**Validation summary**Serial numberParametersAcceptance criteriaObservation01Precision(a) System precision %RSDNMT 1.5%0.0968(b) Method precision %RSDNMT 1.5%0.2799502SpecificityNo considerable absorbance of any other component of formulation at *λ*~max~ of analyte or at detection wavelengthNo absorbance observed at 275 nm03Accuracy (by recovery)% Recovery100% ± 2%100.12%%RSDNMT 1.5%1.1777%% Deviation from accuracy±1.5%080%: +01.46100%: −00.77120%: −00.3204LinearityCoefficient of correlation*r*^2^: 0.997(*r*^2^) NLT 0.99805Ruggedness%RSD: NMT 1.5%%RSD: 0.157206Robustness%RSD: NMT 1.5%Original condition: +0.72Changed condition: −0.8207Limit of detection and limit of quantitationLOD145.2 mgLOQ440.00 mgNMT, not more than; NLT, not less than.

Discussion {#Sec7}
==========

The method was validated with respect to linearity, accuracy, precision, specificity, robustness, ruggedness, LOD, and LOQ. The method was established according to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines. BT~10~M exhibited maximum absorption at 275 nm and obeyed Beer\'s law in the concentration range of 50 to 150 μg/ml. The proposed method for the determination of BT~10~M showed linear regression *y* = 0.005x + 0.025 with a coefficient correlation (*r*^2^) of 0.997 (Figure [1](#Fig1){ref-type="fig"}). The precision was determined by the relative standard deviation of the six-assay sample of BT~10~M, and the assay of each was calculated and the obtained relative standard deviation of % assay was less than 1.5%. The percentage recovery for BT~10~M was found in the range of 98.97% to 99.83% which indicates that the developed method was simple, rapid, and precise. LOD was found to be 145.2 and limit of quantitation to be 440.0. The proposed method will be suitable for the analysis of newly synthesized pyrimidine derivative (BT~10~M) in bulk dosage form.Figure 1**Linearity plot.** The BT10M absorbance response in the concentration range of about 50 mcg/ml to 150 mcg/ml was found to be linear to the analyte concentration in the solution with a correlation coefficient (r2) of 0.997.

Experimental {#Sec8}
============

Validation {#Sec9}
----------

The methods were validated with respect to linearity, accuracy, precision, specificity, ruggedness, robustness, limit of detection (LOD), and limit of quantitation (LOQ).

### Linearity {#Sec10}

The linearity of an analytical method is its ability to elicit test results that are directly, or by a well-defined mathematical transformation, proportional to the concentration of analyte in the samples within a given range. For assay determination, the concentration of BT~10~M is 100 μg/ml. So the working range of analyte was set between 50, 62.5, 75, 87.5, 100, 112.5, 125, 137.5 and 150 μg/ml to show the linearity of the curve obtained. The observations and calibration curve are shown in Table [2](#Tab2){ref-type="table"} and Figure [1](#Fig1){ref-type="fig"}.Table 2**Linearity table of BT** ~**10**~ **M in working standard**Serial numberApproximate concentration (μg/ml)Average absorbance at 275 nm150.00.299262.50.361375.00.458487.50.5115100.00.5696112.50.6517125.00.7148137.50.8039150.00.866

### Accuracy (by recovery test) {#Sec11}

Accuracy of method is by shown by recovery study and spiking working standard in the placebo at levels 80%, 100%, and 120% of the working standard. Recovery study was performed by spiking in BT~10~M to the placebo at levels 80%, 100%, and 120% of working standard. The samples were prepared according to the assay procedure. The results are shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}.Table 3**Accuracy reading**Level (Approximate)Standard added (mg)Absorbance at 275 nmStandard recovered (mg)%RecoveryMean recovery%RSD80%40.50.45840.4399.8399.37%0.43660.4510.459100%50.80.56750.28098.970.5610.574120%60.10.67059.68099.300.6760.673Table 4**Deviation from recovery**Level (Approximate)Actual concentration (μg/ml)Concentration calculated (mg/ml)Accuracy (%)% Deviation80%080.75081.9289101.46+01.46100%100.40099.6269099.23−00.77120%121.05120.6626099.68−00.32

The percentage recovery for BT~10~M was found in the range of 98.97% to 99.83% with an overall relative standard deviation (%RSD) of 0.4366. From the data obtained which was given in Table [3](#Tab3){ref-type="table"}, the method was found to be accurate. Formula of standard deviation was SD = (xi − *x*/*n* − 1)1/2 if *n* is very large. In case of very small data, SD = (xi − *x*/*n*)1/2.

### Precision {#Sec12}

The precision of an analytical method is the degree of agreement among individual test results when the method is applied repeatedly to multiple sampling of homogenous sample. The precision of an analytical method is usually expressed as the standard deviation or relative standard of a series of measurements. Assay preparation and standard preparation were prepared as per method of analysis of six BT~10~M assay sample preparations as per the experimental conditions in method of analysis. Calculated percent of BT~10~M in each assay sample percent by spectrophotometry and the results and observation are summarized in Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}.Table 5**System precision data of BT** ~**10**~ **M working standard solution**Serial numberAbsorbance at 275 nm10.56620.56530.56540.56650.56660.565Average0.565%RSD0.0968Weight of BT~10~M WS = 50.0 mg.Table 6**Method precision data for estimation of BT** ~**10**~ **M**AssaySample weight (mg)Absorbance% Assay150.20.576101.75250.40.576101.29350.20.572101.02450.80.580101.22550.00.569100.96650.70.579101.37Average101.2683%RSD0.27995

### Assay {#Sec13}

$$\%\mspace{2mu}\mathbf{Assay} = \frac{{Abs}.\mspace{2mu}{of}\mspace{2mu} Smp.}{{Abs}.\mspace{2mu}{of}\mspace{2mu}{standard}} \times \frac{Wt.\mspace{2mu}{of}\mspace{2mu}{standard}}{Dil.\mspace{2mu}{factor}} \times \frac{Dil.\mspace{2mu}{factor}}{Wt.\mspace{2mu}{of}\mspace{2mu} Smp} \times 100$$

The precision will be determined by the relative standard deviation of the six-assay sample of BT~10~M, and the assay of each is calculated and the obtained relative standard deviation of % assay should be less than 1.5%. The %RSD shows that precision of the method was satisfactory.

### Specificity {#Sec14}

Specificity study is designed to prove that the BT~10~M in the solution gives maximum absorbance at wavelength 275 nm, and there is no interference from the solvent. The purpose of this study is to establish the fact that inherent chemical stability of the molecule remains intact during its existence. If any degradation product formed, it can be monitored and resolved to quantify the nature and extent of degradation. For this, the spectrum of BT~10~M, placebos are studied. The sample preparation is as per methodology. The spectrum of BT~10~M is shown in Figure [2](#Fig2){ref-type="fig"}.Figure 2**Spectrum of BT** ~**10**~ **M.**

For the spectrophotometric method, no other component of formulation shows considerable absorbance at the *λ*~max~ of the analyte or at the detection wavelength of the subject analyte. In this case of BT~10~M, the detection wavelength is 275 nm. The placebo solution under the same condition does not show any absorbance at 275 nm.

### Ruggedness {#Sec15}

The ruggedness of the analytical method is the degree of reproducibility of test results obtained by the analysis of the sample on different days, by different chemist using different instruments. In this study, two individual assay sample preparations of BT~10~M drug product were prepared by different chemists for analysis. Six (6) replicate observations of the same standard solution were obtained as well as six observations of different sample solution were recorded. The assay percentage of each sample was calculated in each case. The results are summarized in Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"}.Table 7**System precision data of BT** ~**10**~ **M working standard solution**Serial numberAbsorbance at 275 nm10.55920.56130.56040.56150.56060.561Average0.560%RSD0.14571Weight of BT~10~M: 49.8 mg.Table 8**Method precision data for BT** ~**10**~ **M**AssaySample weight (mg)Absorbance% Assay150.20.566100.27250.50.572100.73350.80.582101.94450.70.578101.45550.20.568100.64650.90.579101.23Average101.0433%RSD0.6041Table 9**Mean % assay and %RSD**Chemist AChemist BAverage%RSD101.2683101.0433101.15580.1572

The ruggedness (inter-day precision) will be determined by the relative standard deviation of the results of assay of two different chemists on different days.

### Robustness {#Sec16}

The robustness of an analytical method is a measure of its capacity to remain unaffected by small but deliberate variations in method parameters and provides an indication of its reliability under normal usage. Method robustness was determined by analyzing the same sample at normal operating conditions and also by changing some operating analytical conditions. The result and observation are summarized in Table [10](#Tab10){ref-type="table"}.Table 10**Percentage deviation for sample under both conditions**ParameterOriginal conditionChanged conditionsDilution mediumAcetonitrile:methanolAcetonirile:methanol1:11:2Assay in %101.98100.44% Deviation from mean assay value obtained in precision studies+00.72−00.82

The robustness will be determined by the relative standard deviation of the results of assay of two different conditions by a change in original parameter.

### Limit of detection and limit of quantitation {#Sec17}

#### Limit of detection {#Sec18}

LOD is defined as the lowest concentration of an analyte in a sample that can be detected, not quantified.

#### Limit of quantitation {#Sec19}

The lowest concentration of an analyte in a sample that can be determined with acceptable precision and accuracy under the stated operational conditions of the method.$$\begin{matrix}
\left. \mathbf{L}\mathbf{O}\mathbf{D}:\mspace{2mu} 3.3\left( {\mathbf{S}\mathbf{D}} \right)/\mathbf{Slope} \right. \\
\left. 3.3\left( 0.200 \right)/0.005\mspace{2mu}\left\lbrack {\mathbf{S}\mathbf{D} = 0.2200} \right\rbrack \right. \\
{= 145.2\mspace{2mu}\mathbf{mg}} \\
\left. 2.\mspace{2mu}\mathbf{L}\mathbf{O}\mathbf{Q}:\mspace{2mu} 10\left( {\mathbf{S}\mathbf{D}} \right)/\mathbf{Slope} \right. \\
\left. 10\left( 0.2200 \right)/0.005 \right. \\
{= 440.00\mspace{2mu}\mathbf{mg}} \\
\end{matrix}$$

Conclusions {#Sec20}
===========

All the validation parameters for all the developed methods were studied as per ICH guidelines. All the methods were found to be accurate, simple, specific, selective, precise, and reproducible. Hence, the method can be used for routine analysis of BT~10~M in bulk dosage form.
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